BCRX Biocryst Pharmaceuticals Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 0 P/E
- 55.96 P/S
- 10.02 P/B
- -0.68 EPS
- -229.93% Cash ROIC
- 1.26 Cash Ratio
- 0 / 0% Dividend
- 927,018.00 Avg. Vol.
- 72.32M Shares
- 755.02M Market Cap.
BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...
Motley Fool - Apr 1, 2015
Dakota Financial News - Apr 23, 2015
Schaeffers Research (blog) - Mar 31, 2015
Top Gainers Pre-Market Trading – Charter Communications, Movado Group ... - FxPips.com
Smarter Analyst - Mar 25, 2015
TheStreet.com - Apr 2, 2015
Needham & Company LLC Analysts Give BioCryst Pharmaceuticals a $15.00 ... - sleekmoney
Benzinga - Apr 20, 2015
Markets Wired - Apr 9, 2015
BioCryst Pharmaceuticals Receives $16.12 Consensus Target Price from ... - Mideast Time
Dakota Financial News - Apr 20, 2015
Seeking Alpha (registration) - Jan 27, 2015
FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary ... - GlobeNewswire (press release)
wsnewspublishers - Mar 24, 2015
Closing Bell Reports: BioCryst Pharmaceuticals, Inc. (BCRX), Zillow Group, Inc ... - WallStreet Scope